Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

Asthma is a common respiratory disease characterized by chronic airway inflammation. Dexmedetomidine (DEX), a highly selective alpha 2 adrenergic receptor agonist, has been shown to participate in regulating inflammatory states and thus exert organ protective actions. However, the potential of DEX in asthma is still unknown. This study is aimed at investigating the role of DEX in a mouse model of house dust mite- (HDM-) induced asthma and exploring its underlying mechanism. Here, we found that DEX treatment significantly ameliorated airway hyperresponsiveness, airway inflammation, and airway remodeling in the asthmatic mice, which were similar to the efficacy of the reference anti-inflammatory drug dexamethasone. In addition, DEX reversed the increased expression of toll-like receptor 4 (TLR4) and its downstream signaling adaptor molecule nuclear factor-kappa B (NF-kappa B) in the lung tissue of asthmatic mice. Furthermore, these protective effects of DEX were abolished by yohimbine, an alpha 2 adrenergic receptor antagonist. These results indicate that DEX is capable of ameliorating airway inflammation and remodeling in asthmatic mice, and this protective effect is associated with the inhibition of the TLR4/NF-kappa B signaling pathway.

Automated summary

The study found that DEX can alleviate airway hyperresponsiveness, inflammation, and remodeling in asthmatic mice, similar to the anti-inflammatory drug dexamethasone. Furthermore, DEX inhibited the activation of the TLR4/NF-kappa B signaling pathway in the lung tissue of asthmatic mice. Therefore, DEX may have potential therapeutic effects in asthma.